Caspase-3/7 Inhibitor II

A tetrapeptidyl aldehyde that acts as a potent, reversible and active site binding inhibitor of caspases-3 and -7 (IC₅₀ = 3.2 nM and 22.6 nM, respectively) and displays ~100-fold greater selectivity over caspases-8 and -9 (IC₅₀ = 577.6 nM and 364.7 nM, respectively). Offers protection against Camptothecin (Cat. No. 208925), and anti-Fas-mediated apoptosis in Jurkat T cells.

A tetrapeptidyl aldehyde that acts as a potent, reversible and active site binding inhibitor of caspases-3 and -7 (IC₅₀ = 3.2 nM and 22.6 nM, respectively) and displays ~100-fold greater selectivity over caspases-8 and -9 (IC₅₀ = 577.6 nM and 364.7 nM, respectively). Offers protection against Camptothecin (Cat. No. 208925), and anti-Fas-mediated apoptosis in Jurkat T cells.

Note: aldehyde-based inhibitors are less cell-permeable than FMK-based inhibitors, so higher concentrations may be required for cell-based inhibition studies (e.g. 100 µM).

Cell permeable: no

Primary Target
caspase-3, caspase-7

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 3.2 nM and 22.6 nM, against caspases-3 and -7, respectively

Packaged under inert gas

Toxicity: Standard Handling (A)

Ac-Asp-Asn-Leu-Asp-CHO

Single main spot with additional trace spot by TLC

Yoshimori, A., et al. 2004. BMC Pharmacol.4, 7.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany